EN
中文 EN
Company News
Home >Newsroom >Company News
ALL
2024
2023
2022
2021
2020
2019
2018
2016
2015
2014
2013
2012
2007
2019.02.01
CanSinoBIO Submitted NDA/BLA Application for Meningococcal Conjugate Vaccine
2019.01.14
CanSinoBIO has signed a clinical supply agreement with VaxYnethic, an Italian biotech company for human vaccine development
2019.01.02
CanSinoBio Submitted Clinical Trial Application of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）to NMPA
2018.10.31
CanSinoBIO’s Protein-based Pneumococcal Vaccine Candidate Received Clinical Approval from Chinese Regulatory Agency NMPA
2018.09.14
New UK-China biotech collaboration to develop shingles vaccine
2018.03.22
National Research Council contribution plays key role in newly approved Ebola vaccine
2016.08.03
CanSino Submits a Clinical Trial Application for the Component DTP Diptheria Tetanus Pertussis Combo Vaccine (Adults, Teenagers and Children Above 6 Years Old)
2016.03.24
World TB Day is March 24. Help us bring an end to the epidemic by supporting TB vaccine research.
2016.02.15
Cansino Biotechnology: Meningococcal Group ACYW135 Quadrivalent Conjugate Vaccine is Approved for Clinical Trial
2016.02.15
Cansino Biotechnology: Meningococcal Group AC Bivalent Conjugate Vaccine, Freeze Dried is Approved for Clinical Trial
1234567